Zentalis Pharmaceuticals
ZNTL
114 hedge funds and large institutions have $229M invested in Zentalis Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 29 increasing their positions, 32 reducing their positions, and 19 closing their positions.
1,976% more call options, than puts
Call options by funds: $2.89M | Put options by funds: $139K
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
125% more capital invested
Capital invested by funds: $102M → $229M (+$127M)
79% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 19
12% more funds holding
Funds holding: 102 → 114 (+12)
5.15% more ownership
Funds ownership: 61.41% → 66.56% (+5.2%)
9% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.92M |
| 2 |
O
OrbiMed
New York
|
+$5.55M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$3.79M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.65M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$3.74M |
| 2 |
Millennium Management
New York
|
-$2.5M |
| 3 |
Jane Street
New York
|
-$1.9M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$1.83M |
| 5 |
Barclays
London,
United Kingdom
|
-$1.73M |
ZNTL Hedge Fund Activity: Q2 2026 in Review
114 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q2 2026, worth a combined $229M — up 125% from $102M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new ZNTL positions and 19 closed out — a net gain of 15 holders — while 29 added to existing stakes and 32 trimmed.
The largest buyer was BlackRock, adding an estimated $9.92M. The largest seller was D.E. Shaw & Co, cutting an estimated $3.74M.
- 114 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q2 2026, up from 102 in Q1 2026.
- Funds reported $229M of Zentalis Pharmaceuticals stock for Q2 2026, up 125% quarter-over-quarter.
- 34 funds opened new Zentalis Pharmaceuticals positions in Q2 2026 and 19 closed out, a net change of +15 holders.
- The largest Zentalis Pharmaceuticals buyer in Q2 2026 was BlackRock, an estimated $9.92M added.
- The largest Zentalis Pharmaceuticals seller in Q2 2026 was D.E. Shaw & Co, an estimated $3.74M sold.
Based on aggregated 13F filings for Q2 2026.